Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

patients with metastatic osteosarcoma treated in earlier Phase 2 studies. The biological effects and safety of L-MTP-PE are further supported by data from 7 other Phase 1 and 2 clinical studies performed under IND, in which an additional 197 patients received at least one dose of L-MTP-PE.

L-MTP-PE was granted orphan drug status in the United States in 2001. The NDA for L-MTP-PE was submitted to the U.S. Food and Drug Administration (FDA) in October 2006 and was accepted for review in December 2006.

The FDA's Oncologic Drugs Advisory Committee, or ODAC, met in May 2007 and voted 12 to 2 that the results of the Company's Phase 3 trial do not provide substantial evidence of effectiveness of L-MTP-PE in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy. In July 2007, following a meeting with the FDA, the Company announced plans to collect, analyze and submit additional data for L-MTP-PE to the FDA, in an amendment to the NDA, by the first quarter of 2008. In August 2007 the FDA, considering ODAC's recommendation, issued a not approvable letter to the Company after completing the review of the NDA for L-MTP-PE. In this letter, the FDA requested data from additional clinical trials to demonstrate the benefit of L-MTP-PE, as well as information or clarification with respect to other sections of the NDA.

IDM Pharma also is seeking marketing approval from the European Medicines Agency (EMEA) for the use of L-MTP-PE, or MEPACT as it is known in Europe. L-MTP-PE was granted orphan drug status in Europe in 2004. The Marketing Authorization Application (MAA) for L-MTP-PE was submitted to the EMEA and accepted for review in November 2006. The EMEA application is currently under review and the Company continues to work closely with the regulatory body by providing as much additional data as possible and responding to ongoing inquiries from reviewers. The Company expects that the Committee for Human Medicina
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... enabled more generic drugs to inundate the market, thereby ... Pharmaceutical Manufacturing industry. According to data from Industry ... has cost the industry $1.8 and $2.5 billion in ... brand-name drugs losing patent exclusivity, which has hampered revenue ...
(Date:9/21/2014)... September 21, 2014 The Illinois ... will host a statewide symposium ( tinyurl.com/ILBHC14 ) ... and their Families. Sponsored by the VNA Foundation, ... Cash Grant, and Health & Disability Advocates, the ... the Hilton Hotel in Springfield, IL. The ...
(Date:9/21/2014)... -- Young women starting college understand the benefits of ... eat. But they aren,t confident they can follow through ... study. The study involved 268 female college ... Exercising and Eating Right program. The students answered food-related ... if they were very busy with school work, were ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 ... Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 is a ... and Chinese Fenofibrate (CAS 49562-28-9) industry. The ... Fenofibrate (CAS 49562-28-9) including its classification, application ... and China’s top manufacturers of Fenofibrate (CAS ...
(Date:9/21/2014)... An experienced review website in the ... ranking list and announced that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ), ... , There has been a boom in websites ... in an increase in the number of web hosting ... very affordable prices. VPS (Virtual Private Server) is the ...
Breaking Medicine News(10 mins):Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News: College Women Can Use Food Strategies, Study Finds 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2
... the FDA could be one of the most significant advances in ... say doctors involved in the research., ,Diabetes is a disease ... body (type 1 diabetes) or the body does not effectively use ... another hormone -- amylin -- to aid in the treatment of ...
... survey is a worldwide investigation of sociocultural and political ... network of social scientists. It includes questions about how ... their lives. ,It showed that average happiness has ... War II, although incomes have risen. ,The analysis ...
... death in many people, but previous research has not looked ... study focuses on depression in elderly people living in the ... ,The study, involved 250 participants in a community health program. ... of depression and then did so again at 18 months. ...
... care unit patients who receive a preventative round of antibiotics ... more likely to survive their ICU stay. // ... between ICU patients who were given antibiotics and those who ... antibiotics to kill harmful bacteria in the mouth, stomach, and ...
... be at risk for experiencing dangerous falls. ,Researchers studied more ... asked if they // had fallen in the last 12 months, ... medical attention for the falls. ,They also brought all ... history report. ,Results of the study show nearly three ...
... receives for breast cancer be putting her at higher ... ,Studies finds women who underwent simple mastectomy and radiotherapy ... had a radical mastectomy and no radiotherapy to later ... cancer rates were noted among a group of women ...
Cached Medicine News:Health News:ICU Survival can be improved by Antibiotic use 2
(Date:9/19/2014)... , Sept. 19, 2014  Diplomat, the nation,s largest ... David Dreyer to the Board of Directors on ... and will also serve as chair of the Audit ... years of accounting, financial, compliance and operating experience in ... has served as chief financial officer, chief operating officer ...
(Date:9/19/2014)... WOONSOCKET, R.I. , Sept. 19, 2014 Five MinuteClinic ... Memphis metropolitan area. Three clinics opened in ... earlier this month. A fourth clinic will be added in ... in Bartlett is expected to open October ... medical clinics in the United States . ...
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
... (NASDAQ: SVA ), a leading provider of biopharmaceutical ... results for the period ended June 30, 2011. ... increased 52.5% year-over-year to $15.7 million, compared to $10.3 million. ... EPS was $0.02 per share. Cash and cash ...
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced ... 2011, as Vice President, Finance and Chief Financial Officer. Mr. ... 13 years before departing in March to work for a ... who has been a key contributor to Arena," said Jack ...
Cached Medicine Technology:Sinovac Reports Unaudited Second Quarter 2011 Financial Results 2Sinovac Reports Unaudited Second Quarter 2011 Financial Results 3Sinovac Reports Unaudited Second Quarter 2011 Financial Results 4Sinovac Reports Unaudited Second Quarter 2011 Financial Results 5Sinovac Reports Unaudited Second Quarter 2011 Financial Results 6Sinovac Reports Unaudited Second Quarter 2011 Financial Results 7Sinovac Reports Unaudited Second Quarter 2011 Financial Results 8Sinovac Reports Unaudited Second Quarter 2011 Financial Results 9Sinovac Reports Unaudited Second Quarter 2011 Financial Results 10Sinovac Reports Unaudited Second Quarter 2011 Financial Results 11Sinovac Reports Unaudited Second Quarter 2011 Financial Results 12Sinovac Reports Unaudited Second Quarter 2011 Financial Results 13Sinovac Reports Unaudited Second Quarter 2011 Financial Results 14Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 2Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 3
... Axiovert 40 inverted ... you have ever expected from a microscope in ... outstanding quality, and functionality. Axiovert 40 has been ... safe as possible thus increasing the efficiency ...
... is an advanced inverted microscope ... exclusive CFI60 optical system, extendible ... it ideal for high precision, ... inverted microscope to take full ...
... Eclipse TE2000E is an advanced inverted microscope ... five imaging ports, high resolution CFI60 optics, ... perfect imaging workstation. In addition, its super-nanoprecision ... control is perfect for precise imaging in ...
... The IX71's modular frame ... 9 access ports for ... devices. Up to four ... access to a primary ...
Medicine Products: